Shopping Cart
- Remove All
Your shopping cart is currently empty
Monalizumab
🥰Excellent
Catalog No. T76691Cas No. 1228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
Monalizumab
Monalizumab
🥰Excellent
Catalog No. T76691Cas No. 1228763-95-8
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $438 | In Stock | |
| 5 mg | $987 | In Stock | |
| 10 mg | $1,380 | In Stock | |
| 25 mg | $1,980 | In Stock | |
| 50 mg | $2,770 | In Stock | |
| 100 mg | $3,730 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Monalizumab"
CCCP
Cited
Carbonyl Cyanide m-Chlorophenylhydrazone, Carbonyl cyanide 3-chlorophenylhydrazone
T7081555-60-2
CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.
- $41
Size
QTY
CitedPrexasertib
LY2606368
T43101234015-52-1
Prexasertib (LY2606368) is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
- $48
Size
QTY
Deucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
Baricitinib Cited
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
- $43
Size
QTY
CitedRO8191 Cited
RO4948191, CDM-3008
T22142691868-88-9
RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.
- $38
Size
QTY
CitedVadimezan Cited
NSC 640488, DMXAA, ASA-404, 5,6-Dimethylxanthenone-4-acetic Acid
T6273117570-53-3
Vadimezan (DMXAA) is a vascular disrupting agent, a murine STING agonist, and an inducer of cytokines such as type I IFN. Vadimezan has antitumor activity and induces a rapid cessation of blood flow in tumors without affecting blood flow in normal tissues.
- $48
Size
QTY
CitedPD0166285
PD-166285
T6931185039-89-8
PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
- $52
Size
QTY
CHK1-IN-3
T107912097252-39-4In house
CHK1-IN-3 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 0.4 nM).
- $195
Size
QTY
CHK1-IN-4 hydrochloride
CHK1-IN-4 hydrochloride（2120398-41-4 Free base）
T10792LIn house
CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1). CHK1-IN-4 hydrochloride potently inhibits chk1 phosphorylation in the tumor cells. CHK1-IN-4 hydrochloride has anti-tumor activity.
- $197
Size
QTY
Cridanimod
XBIO-101, CMA, 10-carboxymethyl-9-acridanone
T531738609-97-1
Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.
- $30
Size
QTY
Select Batch
Concentration:6.66 mg/mL
Purity:> 95%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC). |
| In vitro | Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14. The results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor models[1]. |
| In vivo | Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14. The results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor models[1]. |
| Molecular Weight | 147 kDa (average) |
| Cas No. | 1228763-95-8 |
Storage & Solubility Information
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Monalizumab | purchase Monalizumab | Monalizumab cost | order Monalizumab | Monalizumab in vivo | Monalizumab in vitro | Monalizumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.